KPV vs BPC-157: Complete 2026 Comparison
Side-by-side comparison of KPV and BPC-157: mechanism, common use cases, dosing protocols from named experts, vendor availability, and expert opinion. Both are framed as research compounds.
TL;DR Table
| Factor | KPV | BPC-157 |
|---|---|---|
| Class | PEPTIDE | PEPTIDE |
| Aliases | ["Lys-Pro-Val", "\u03b1-MSH C-terminus"] | ["Body Protection Compound 157", "Pentadecapeptide"] |
| Mechanism | Inhibits NF-κB pathway; reduces pro-inflammatory cytokines (IL-1, TNF-α). | Promotes angiogenesis (new blood vessel formation), modulates nitric oxide, upregulates growth hormone receptors locally. |
| What it's researched for | Anti-inflammatory action especially in gut and skin. Tanner mentions oral TB and KPV as related healing peptides. | Accelerates tendon, ligament, muscle, and gut healing. Some evidence for neuroprotection. Tanner uses BPC-157 from APR for soft tissue healing. |
| Dosing mentions tracked | 54 | 104 |
| Vendor recs tracked | 14 | 36 |
| PubMed papers | 15 | 15 |
Mechanism Comparison
BPC-157
Promotes angiogenesis (new blood vessel formation), modulates nitric oxide, upregulates growth hormone receptors locally.
What Each is Researched For
KPV research areas
Anti-inflammatory action especially in gut and skin. Tanner mentions oral TB and KPV as related healing peptides.
BPC-157 research areas
Accelerates tendon, ligament, muscle, and gut healing. Some evidence for neuroprotection. Tanner uses BPC-157 from APR for soft tissue healing.
Dosing Mention Comparison
KPV dosing
- Vigorous Steve: 2 mg per day localized injection at site of injury (00:05:46)
- Steve: 2 mg per day in quad tendon recovery stack (00:05:48)
- Steve: 2 mg daily, localized at injury site (00:05:48)
- Vigorous Steve: 2 mg daily as part of injury recovery stack (00:05:48)
- Steve: Steve reported using 2 mg/day localized at injury site. (00:05:48)
BPC-157 dosing
- speaker_1: Speaker reported using 200-1,000 mcg BPC-157 via subcutaneous, intramuscular, or intra-articular injection positioned as close to soft... (00:00:22)
- speaker_1: Speaker discussed injury recovery: serious tissue damage addressed with 3-month treatment cycles rather than 3-week protocols. No... (00:00:29)
- Narrator: A clinic reportedly offers a 'glow stack' combining GHK copper, BPC-157, and TB-500, marketed for anti-aging, recovery, and inflammation... (00:00:47)
- narrator: Users report oral BPC-157 for gut inflammation; injectable BPC-157 for chronic systemic inflammation and multiple joint issues. (00:00:50)
- speaker_1: Single oral dose of either 1 mg, 3 mg, or 6 mg BPC-157 on an empty stomach during phase 1A of the PCO-02 trial. (00:00:55)
Side Effect Notes
Anecdotal reports for both compounds vary by route, dose, and individual. Neither should be treated as an approved medication. Consult a qualified clinician.
When To Choose Which
Comparison depends on research question, available source quality, and individual risk tolerance. See the full profiles for KPV and BPC-157 for context-specific details.
Can You Stack Them?
Stacking decisions should be evaluated by qualified professionals with attention to dose attribution, source quality, and outcome tracking. This page is a research aggregator and does not recommend stacking protocols.
FAQ
Which has more research?
KPV has 15 PubMed citations indexed; BPC-157 has 15.
Which has more vendor coverage?
KPV: 14 tracked vendor recommendations. BPC-157: 36.
Are they approved drugs?
Both are framed on this site as research compounds. Verify current FDA status and state-specific rules before any decision.